Compare iShares MSCI Japan ETF (EWJ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Smith & Nephew plc — how do they compare? iShares MSCI Japan ETF trades at $97.45 (market cap $23.87B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: iShares MSCI Japan ETF is far larger — about 2.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Smith & Nephew plc for 120 Days on average.
| EWJ | SNN | |
|---|---|---|
Market Cap | $23.87B | $11.10B |
Volume | 5,412,820 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $37.17 |
52-Week Low | $78.36 | $26.42 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.44, down 0.9% on the day amid mixed technical signals. The ETF shows neutral momentum with RSI readings around 50 and faces immediate resistance at $98. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes while facing fiscal challenges and yen volatility.
The outlook remains balanced with international ETF performance showing strength but Japanese equities facing headwinds from rising yields and currency pressures. Key risks include BOJ policy missteps and global bond market volatility, while potential catalysts include sustained international diversification trends and yen stabilization efforts.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
